Truist Securities adjusted its outlook for Sangamo BioSciences, reducing the price target on the company's shares to $5 from ...

Analyst Yanan Zhu of Wells Fargo maintained a Hold rating on Sangamo Biosciences (SGMO – Research Report), retaining the price target of ...

NEW YORK, NY / ACCESSWIRE / January 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...

Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...

Pfizer cuts losses on near-approval hemophilia gene therapy, adding to troubled Sangamo's woes Pfizer plans to share the results at an upcoming medical congress. Areas of interest beyond the ...

NEW YORK, NY / ACCESSWIRE / January 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of ...

[Click here for information about joining the class action] During post-market hours on December 30, 2024, Sangamo announced that Pfizer, with whom the Company was co-developing hemophilia A ...

In addition to the Genentech partnership, Sangamo continues to work closely with Pfizer (NYSE:PFE) on the development of giroctogene fitelparvovec (giro-vec), a gene therapy for hemophilia A. Positive ...

In addition to the Genentech partnership, Sangamo continues to work closely with Pfizer (NYSE:PFE) on the development of giroctogene fitelparvovec (giro-vec), a gene therapy for hemophilia A.

What Happened? On December 30, 2024, after market hours, Sangamo disclosed that Pfizer Inc. (“Pfizer”) had notified the Company of its termination of a partnership to develop a hemophilia A ...